Kentaro Inamura1, Mai Yamauchi1, Reiko Nishihara1, Paul Lochhead1, Zhi Rong Qian1, Aya Kuchiba1, Sun A Kim1, Kosuke Mima1, Yasutaka Sukawa1, Seungyoun Jung1, Xuehong Zhang1, Kana Wu1, Eunyoung Cho1, Andrew T Chan1, Jeffrey A Meyerhardt1, Curtis C Harris1, Charles S Fuchs1, Shuji Ogino1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (KI, MY, RN, PL, ZRQ, AK, SAK, KM, YS, JAM, CSF, SO); Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD (KI, CCH); Department of Nutrition, Harvard School of Public Health, Boston, MA (RN, AK, KW); Gastrointestinal Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA (SJ, XZ, EC, ATC, CSF); Department of Dermatology, The Warren Alpert Medical School of Brown University, Province, RI (EC); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO); Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA (SO).
Abstract
BACKGROUND: Hypomethylation in long interspersed nucleotide element-1 (LINE-1) and high-degree microsatellite instability (MSI-high) in colorectal cancer (CRC) have been associated with inferior and superior survival, respectively; however, it remains uncertain whether the prognostic association of LINE-1 hypomethylation differs by MSI status. We hypothesized that the adverse prognostic association of LINE-1 hypomethylation might be stronger in MSI-high CRCs than in microsatellite stable (MSS) CRCs. METHODS: Utilizing 1211 CRCs in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined patient survival according to LINE-1 hypomethylation status in strata of MSI status. A Cox proportional hazards model was used to compute multivariable CRC-specific mortality hazard ratios (HRs) for a 10% decrease in LINE-1 methylation level (range = 23.1-93.1%), adjusting for potential confounders, including CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. Statistical tests (log-rank test, chi-square test, and likelihood ratio test) were two-sided. RESULTS: In MSI-high cancers, the association of LINE-1 hypomethylation with higher mortality (HR = 2.45, 95% confidence interval [CI] = 1.64 to 3.66, P < .001) was stronger than that in MSS cancers (HR = 1.10, 95% CI = 0.98 to 1.24, P = .11) (P interaction < .001, between LINE-1 and MSI statuses). In MSI-high cases with CRC family history, the association of LINE-1 hypomethylation with higher mortality (HR = 5.13, 95% CI = 1.99 to 13.2; P < .001) was stronger than that in MSI-high cases without CRC family history (HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (P interaction = .02, between LINE-1 and CRC family history statuses). CONCLUSIONS: The association of LINE-1 hypomethylation with inferior survival is stronger in MSI-high CRCs than in MSS CRCs. Tumor LINE-1 methylation level may be a useful prognostic biomarker to identify aggressive carcinomas among MSI-high CRCs.
BACKGROUND: Hypomethylation in long interspersed nucleotide element-1 (LINE-1) and high-degree microsatellite instability (MSI-high) in colorectal cancer (CRC) have been associated with inferior and superior survival, respectively; however, it remains uncertain whether the prognostic association of LINE-1 hypomethylation differs by MSI status. We hypothesized that the adverse prognostic association of LINE-1 hypomethylation might be stronger in MSI-high CRCs than in microsatellite stable (MSS) CRCs. METHODS: Utilizing 1211 CRCs in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined patient survival according to LINE-1 hypomethylation status in strata of MSI status. A Cox proportional hazards model was used to compute multivariable CRC-specific mortality hazard ratios (HRs) for a 10% decrease in LINE-1 methylation level (range = 23.1-93.1%), adjusting for potential confounders, including CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. Statistical tests (log-rank test, chi-square test, and likelihood ratio test) were two-sided. RESULTS: In MSI-high cancers, the association of LINE-1 hypomethylation with higher mortality (HR = 2.45, 95% confidence interval [CI] = 1.64 to 3.66, P < .001) was stronger than that in MSS cancers (HR = 1.10, 95% CI = 0.98 to 1.24, P = .11) (P interaction < .001, between LINE-1 and MSI statuses). In MSI-high cases with CRC family history, the association of LINE-1 hypomethylation with higher mortality (HR = 5.13, 95% CI = 1.99 to 13.2; P < .001) was stronger than that in MSI-high cases without CRC family history (HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (P interaction = .02, between LINE-1 and CRC family history statuses). CONCLUSIONS: The association of LINE-1 hypomethylation with inferior survival is stronger in MSI-high CRCs than in MSS CRCs. Tumor LINE-1 methylation level may be a useful prognostic biomarker to identify aggressive carcinomas among MSI-high CRCs.
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland Journal: J Natl Compr Canc Netw Date: 2011-11 Impact factor: 11.908
Authors: Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris Journal: JAMA Date: 2008-01-30 Impact factor: 56.272
Authors: Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde Journal: Gastroenterol Rep (Oxf) Date: 2013-08-23
Authors: Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: J Natl Cancer Inst Date: 2013-07-22 Impact factor: 13.506
Authors: Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Gut Date: 2015-08-26 Impact factor: 23.059
Authors: Niyati Desai; Dipti Sajed; Kshitij S Arora; Alexander Solovyov; Mihir Rajurkar; Jacob R Bledsoe; Srinjoy Sil; Ramzi Amri; Eric Tai; Olivia C MacKenzie; Mari Mino-Kenudson; Martin J Aryee; Cristina R Ferrone; David L Berger; Miguel N Rivera; Benjamin D Greenbaum; Vikram Deshpande; David T Ting Journal: JCI Insight Date: 2017-02-09
Authors: Mary K Townsend; Hugues Aschard; Immaculata De Vivo; Karin B Michels; Peter Kraft Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Naohiko Akimoto; Melissa Zhao; Tomotaka Ugai; Rong Zhong; Mai Chan Lau; Kenji Fujiyoshi; Junko Kishikawa; Koichiro Haruki; Kota Arima; Tyler S Twombly; Xuehong Zhang; Edward L Giovannucci; Kana Wu; Mingyang Song; Andrew T Chan; Yin Cao; Jeffrey A Meyerhardt; Kimmie Ng; Marios Giannakis; Juha P Väyrynen; Jonathan A Nowak; Shuji Ogino Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Tomotaka Ugai; Jennifer Borowsky; Marios Giannakis; Shuji Ogino; Juha P Väyrynen; Mai Chan Lau; Naohiko Akimoto; Sara A Väyrynen; Melissa Zhao; Rong Zhong; Koichiro Haruki; Andressa Dias Costa; Kenji Fujiyoshi; Kota Arima; Kana Wu; Andrew T Chan; Yin Cao; Mingyang Song; Charles S Fuchs; Molin Wang; Jochen K Lennerz; Kimmie Ng; Jeffrey A Meyerhardt; Jonathan A Nowak Journal: Cancer Immunol Immunother Date: 2021-09-16 Impact factor: 6.630
Authors: Raquel Buj; Izaskun Mallona; Anna Díez-Villanueva; Víctor Barrera; Dídac Mauricio; Manel Puig-Domingo; Jordi L Reverter; Xavier Matias-Guiu; Daniel Azuara; Jose L Ramírez; Sergio Alonso; Rafael Rosell; Gabriel Capellà; Manuel Perucho; Mercedes Robledo; Miguel A Peinado; Mireia Jordà Journal: Oncotarget Date: 2016-03-01